The Drug Missed Its Endpoint. What Does That Actually Mean?

Laboratory instrument beside glowing data streams flowing into a circular target

Few sentences can destroy billions of dollars of market value faster than this one: “The study did not meet its primary endpoint.” Stocks plummet. Headlines pronounce the trial a failure. Analysts downgrade their probability of approval. Investors question whether to continue the program. Sometimes that reaction is deserved. But “missed the endpoint” does NOT necessarily mean “drug doesn’t work.”

What it really means is both simpler and more complicated: the clinical trial did not prove, with enough statistical certainty, that the drug has the treatment effect it was hypothesized to have. That distinction is important. Because while a failed endpoint can indicate that the drug doesn’t work, it can also indicate that the drug works less than we hoped, works on the wrong patients, works on something other than what we measured, or was placed into a trial that simply was not designed to adequately see its effect. And determining which explanation is true is one of the most challenging problems in drug development.

First, what exactly is an endpoint?

An endpoint is the predefined outcome researchers use to determine whether a treatment produced the intended benefit. The FDA defines an endpoint as a precisely defined variable reflecting an outcome of interest that is statistically analyzed to answer a particular research question. Some endpoints measure things patients immediately understand:

  • Did patients live longer?
  • Did their pain improve?
  • Could they walk farther?
  • Were they hospitalized less often?
  • Did their symptoms improve?

Others may measure something we think will predict clinical benefit (aka a surrogate endpoint), like tumor response, progression-free survival, viral load or a biomarker. The FDA makes a critical distinction between these two types of measurements. Clinical outcomes answer the question of whether patients feel better, function better or live longer. Surrogate endpoints stand in place of that final clinical outcome. Before starting a trial, researchers make a scientific bet: If this drug really works, we believe this particular measurement, in this specific group of people, over this defined period of time, will show it. That’s why the primary endpoint isn’t just another number in the final dataset. It’s the main test of the drug’s hypothesis.

Missing it is a big deal

Don’t minimize endpoint failure. FDA describes primary endpoints as the endpoints used to establish a drug’s effects and determine whether the study achieved its objective. FDA’s explanation of its multiple-endpoint guidance is even more straightforward: if a candidate fails to demonstrate an effect on endpoints required for approval, it won’t get approved on the basis of that evidence. That’s why a positive secondary endpoint usually cannot simply be promoted to primary status after the results arrive.

Imagine a company announces:

The study missed its primary endpoint of reducing hospitalizations, but patients receiving the drug showed statistically significant improvement on three secondary measures.

Exciting? Yes. Proof positive that the trial worked? Maybe not. Clinical trials often measure many different outcomes. The more statistical tests you perform, the more likely you are to find something that looks good purely by chance. That’s called the multiplicity problem. The FDA even cautions, “If several endpoints are analyzed without appropriate adjustment for multiplicity, there is an increased likelihood of drawing false conclusions about the effects of the drug.” That’s why endpoints and statistical analysis plans are agreed to in advance of knowing the results. Otherwise, pharmaceutical development would be a game of playing buzzword bingo and picking your winners after the fact.

Drug development is already an exercise in failure

Endpoint misses also need to be viewed in the context of just how difficult drug development actually is. A major analysis from BIO, Informa Pharma Intelligence and QLS Advisors examined 12,728 clinical and regulatory phase transitions across 9,704 drug-development programs from 2011 through 2020.

The numbers are sobering.

Across all indications:

Phase I → Phase II: 52.0%

Phase II → Phase III: 28.9%

Phase III → NDA/BLA: 57.8%

NDA/BLA → Approval: 90.6%

Put everything together and the probability that a drug entering Phase I eventually reached approval was only 7.9%. In other words, roughly 92 out of every 100 clinical-stage development programs did not make it from Phase I to approval in that dataset.

And Phase II—the stage where efficacy is often seriously tested for the first time—was particularly brutal. Fewer than three in ten programs successfully transitioned from Phase II to Phase III. Endpoint failure isn’t an anomaly in pharmaceutical R&D. It’s part of the mathematics of trying to turn biological hypotheses into medicines.

So why does a drug miss an endpoint?

This is where the story gets interesting. A missed endpoint should trigger a much more sophisticated question than “Did the drug fail?” The question should be:

“Why did the trial fail to demonstrate the expected effect?”

There are several very different possibilities.

1ne. The drug simply doesn’t work

Okay, before I get to my list, here’s the caveat that nobody wants to read. Just because you have a compelling mechanism of action doesn’t mean you will have a clinically effective medicine. Drugs can perform marvelously in preclinical models. They can have very persuasive efficacy in animal models. Biomarkers can move exactly as you expect them to. And still not work in human disease. Biology is messy. The pathway you are targeting may not be as crucial to disease as you thought. Other pathways may compensate. Your target may be relevant during one phase of disease progression but not another. And yes, sometimes a failed endpoint is exactly that: Your hypothesis was incorrect. That is terrible science (and investments) but that is also why we run randomized controlled trials.

2wo. The drug works—but the effect is smaller than expected

Clinical trials are based on assumptions. Researchers assume a certain treatment effect and then compute the number of patients required to observe that difference as statistically significant. Let’s say investigators assume the drug will lower the rate of an event by 25%.

What if it only lowers the rate by 12%? That 12% decrease may be real. It might even be meaningful for some patients. But the trial may still not have enough people to demonstrate that statistically. The FDA explicitly warns about the risk of Type II error—inability to prove a treatment effect when one actually exists. Study power is defined as the probability that the trial will detect a predefined treatment effect if that treatment effect really does exist. Thus, a failed endpoint can sometimes mean: There may be an effect, but we just didn’t prove it. That is not the same as showing there is no effect.

3hree. The wrong patients may have been studied

Just because two diseases are given the same diagnostic name doesn’t mean they are biologically the same disease. Cancer has taught pharmaceutical developers this lesson many times over. Patients can have tumors derived from the same organ but have very different molecular drivers – and react completely differently to the same treatment. The same concept applies increasingly to neurological indications, immunology, metabolic disease, and beyond.

Think of a drug that works wonderfully in 25% of patients but does nothing at all in the other 75%. Give it to everybody and you might see no average effect at all. Select the biologically matched 25% and suddenly you have a drug that looks nothing like it did before. Of course, this won’t necessarily save an unpublishable trial. Subgroup analysis after the fact is famously open to fishing expeditions and will usually need prospective validation. But it does highlight one of the most critical questions to ask after an endpoint miss: Was the biology flawed – or was the population too diverse?

4our. The endpoint itself may have been wrong

Here’s an uncomfortable truth about clinical development: We don’t always measure the thing patients care about most. Sometimes we measure what we can realistically measure within the time and budget available.

Overall survival may be enormously meaningful in oncology, for example, but it can take years to measure and can be complicated by treatments patients receive after their disease progresses. FDA notes that progression-free survival may therefore be selected as a primary endpoint in some oncology studies because it can be observed earlier and may be more readily demonstrable. The endpoint therefore becomes a compromise between biology, clinical relevance, statistical power, feasibility and regulatory expectations. That creates an important possibility:

The drug may affect the disease without producing enough change in the particular endpoint selected for the trial.

That doesn’t make the trial positive. But it may tell researchers that they asked the wrong question.

5ive. The control group performed better than expected

This is one of the less glamorous ways trials fail. A drug’s effect is generally judged relative to something: placebo, standard of care or another comparator. The statistical assumptions made before the trial therefore depend partly on what researchers expect to happen in the control arm.

Suppose investigators expect:

Control: 30% event rate

Drug: 20% event rate

That’s a substantial difference.

But imagine the trial produces:

Control: 23%

Drug: 20%

The experimental treatment hasn’t necessarily become less effective in absolute terms. The difference between groups has simply collapsed. Changes in standards of care, better disease management, trial-site behavior and patient selection can all make historical assumptions about the control group wrong. The drug didn’t necessarily change.

The environment around the drug did.

6ix. The trial may have been too short

Some treatments take time before they show a benefit. This is especially true for slowly evolving chronic illnesses. If you are targeting deterioration, not snap improvement, a 12-month trial could theoretically look terrible, while 24 or 36 months allows some separation between treatment and placebo. Longer trials are expensive, use up patent life, and delay regulatory review. You are thus faced with a tough optimization problem: How many months do you need to observe your patients before the biology shines through? Guess too high and a potentially beneficial drug can miss its endpoint.

7even. Dropouts, adherence, and missing data can dilute the signal

Clinical trials don’t take place in a vacuum. Patients go off study drug. Patients miss appointments. Patients withdraw. Patients cross over to other therapies. Investigators make protocol deviations. COVID-19 showed us, in the starkest way, that external factors can negatively impact even the best-designed clinical trials. The more divergence between what was intended and what actually occurred, the more difficult it can be to distinguish a true drug effect. Doesn’t mean you get a free pass on a failed trial. Execution is part of drug development. But when you’re sleuthing through a missed endpoint, conduct of the trial is almost as important as the p-value.

The p-value isn’t a cliff

One of the most misunderstood scenarios occurs when a trial produces something like:

p = 0.051

when the predefined threshold was:

p < 0.05.

Secondary endpoints become clues—not escape hatches.

Sure, strictly speaking, the trial did not meet statistical significance. But it is intellectually dishonest to believe that a compound that achieves p=0.049 works and a compound that gets p=0.051 does not. The cutoff is a rule people make up; it’s not a magic energy barrier. More productive questions include: How big was the treatment effect? What was the confidence interval? Was the treatment effect consistent with other measured endpoints? Was the effect size clinically meaningful? Was the effect observed across all populations being studied? Did secondary endpoints support the pharmacology? Was there a dose-response relationship? Was the safety profile acceptable? The endpoint says nothing about the drug; it just tells us whether we met our arbitrary statistical threshold for success. Everything else tells us what we learned about the drug from the trial.

This distinction is crucial.

When a primary endpoint fails but secondary endpoints look positive, management teams often emphasize those secondary results.

Investors should immediately ask whether those analyses were part of a prespecified multiplicity-controlled testing hierarchy.

FDA guidance notes that secondary endpoints can support the primary endpoint or demonstrate additional clinically important effects. But depending on the statistical testing strategy, failure earlier in the hierarchy can prevent later findings from being interpreted as confirmatory evidence.

That doesn’t make the secondary data useless. It changes what the data mean. They become hypothesis-generating evidence rather than definitive proof. And sometimes those clues become extraordinarily valuable. They can identify a responsive patient population, suggest a better dose, reveal a more appropriate endpoint or provide the rationale for the next trial. But they need to be treated as clues to investigate—not evidence to retrofit into the original hypothesis.

There is another endpoint that matters: clinical relevance

Conversely, a drug may become statistically significant yet fail to reach clinical significance. Consider a large trial that shows a treatment increases a 100-point symptom score by 1.5 points more than placebo. If the trial enrolls enough people, that difference may yield a compelling p-value. But will patients care? Would doctors find it worthwhile? Would payers pay more money for it? Will patients endure side effects to achieve it? Statistical significance addresses the question “Is this difference unlikely to be due to chance under the statistical model?” Clinical significance asks instead “Is this difference large enough to care?” Drug development requires both in the long run. An endpoint can pass its milestones and yet still leave you with a commercially weak drug.

The most dangerous phrase after a failed trial

Whenever you read about a trial that doesn’t meet its primary endpoint, look for this sentence: “Subsequent analyses revealed positive trends.” Often those trends are legitimate. But this is also where confirmation bias can lead us astray. You can slice and dice a large clinical dataset in hundreds of ways—by age, sex, disease severity, region, biomarkers, prior therapy, baseline characteristics and dozens of other variables. Pretty soon you’ll find something that looks interesting. That’s why FDA’s guidance document focuses so much on prespecification and control of multiplicity: The more you look for things, the more likely you are to find something that is wrong. The question isn’t: “Can we identify patients who looked like they benefitted from treatment?” The real question is: “Was there a plausible biological reason why we would have anticipated these patients would benefit – and can we replicate that result in another, prospective trial?” Only replication can distinguish discovery from mining.

What I look for when a company announces an endpoint miss

Forget the sound-bite adjectives. Look at the numbers. Start with the effect size. How big was the difference between the treatment and control groups? Then look at the confidence interval. How precise is that estimate? Consider the p-value, but don’t stop there. How did the actual results compare with the assumptions used to design the study? How did the placebo or control group perform? Are the secondary endpoints pointing in the same direction? What about discontinuation and adherence rates? Were subgroup analyses planned in advance, or uncovered after the database was “unlocked”? Look at dose response. Look at safety. And most importantly, ask: Did this trial falsify the underlying biological hypothesis—or just reveal flaws in the way that hypothesis was tested? Those are two radically different outcomes.

A failed endpoint is information

This may be the key point. Drug development is not a series of successes and failures. It’s an extremely costly process of eliminating uncertainty. Every clinical trial starts with uncertainty over a molecule: Is the target valid? Does the drug reach it? Is the dose right? What patients will respond? How quickly should they respond? What outcome best measures that response? Is the magnitude of that benefit meaningful? Is it worth the risk?

A positive trial answers many of those questions conclusively. A negative trial can as well. Sometimes the conclusion is brutally obvious: Stop working on this drug. Sometimes the conclusion is: Wrong dose. Wrong population. Wrong endpoint. Wrong duration of treatment. Wrong hypothesis about the control arm. Occasionally it’s something like: Interesting biology—but not enough benefit to warrant further investment of $1 billion+. That last point is critical. A drug can show biological activity without being a medicine.

The real meaning of “the endpoint was missed”

When you read that a company’s trial missed an endpoint, don’t mentally convert that statement into: “The drug doesn’t work.” Turn it into: “The experiment failed to provide the prespecified evidence needed to establish the effect the study was designed to demonstrate.” Then ask yourself why. Sometimes the answer will doom the drug. Sometimes it will lead to a new trial. Sometimes it will find a smaller population where the treatment has much more value. And sometimes years of failed follow-up research will do nothing more than confirm what the first failed endpoint was telling everyone upfront.

That is why clinical development is so challenging. The endpoint isn’t just a statistical hurdle placed between the drug company and the FDA. It’s the point at which a hypothesis about human biology is put to the test by actual human biology. And human biology really doesn’t care about your investment thesis, the mechanism-of-action slide, the analyst forecast or how much money is already sunk into development. It just provides the data.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply